Cytek Biosciences, Inc.
CTKBNASDAQHealthcare● Active
$4.04
$-0.05(-1.22%)
Market Cap$521736051
P/E Ratio—
52W High$6.18
52W Low$2.9
Cytek Biosciences, Inc. (CTKB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTKB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.12
Est. -$0.08 · -50.0%
Revenue
$0.04B
Est. $0.04B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
CTKB reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.01 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.08 | -$0.12 | -50.0% | $0.04B | $0.04B | -0.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.02 | -$0.01 | +50.0% | $0.06B | $0.06B | +8.7% |
| ▼ Q4 FY2025 | Nov 5, 2025 | $0.01 | -$0.01 | -200.0% | $0.05B | $0.06B | -11.1% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.02 | $0.01 | +150.0% | $0.05B | $0.05B | -1.6% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.04 | -$0.09 | -125.0% | $0.04B | $0.04B | -2.8% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $0.05 | $0.07 | +40.0% | $0.06B | $0.06B | -3.2% |
| ▲ Q4 FY2024 | Nov 5, 2024 | $0.00 | $0.01 | +166.7% | $0.05B | $0.06B | -15.4% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.12
EPS Est.
-$0.08
EPS Surpr.
-50.0%
Revenue
$0.04B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.02
EPS Surpr.
+50.0%
Revenue
$0.06B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.01
EPS Est.
$0.01
EPS Surpr.
-200.0%
Revenue
$0.05B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.02
EPS Surpr.
+150.0%
Revenue
$0.05B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.04
EPS Surpr.
-125.0%
Revenue
$0.04B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.07
EPS Est.
$0.05
EPS Surpr.
+40.0%
Revenue
$0.06B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.01
EPS Est.
$0.00
EPS Surpr.
+166.7%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2028 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2028 | $-0.14 | $-0.13 | $-0.13 | 1 |
| Q4 FY2027 | $-0.02 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-0.06 | $-0.06 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -50.0% | $4.94 | $4.92 | -0.40% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +50.0% | $4.37 | $4.40 | +0.69% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -200.0% | $3.91 | $4.01 | +2.56% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +150.0% | $3.88 | $3.89 | +0.26% |
| ▼ Q2 FY2025 | May 8, 2025 | -125.0% | $3.73 | $3.79 | +1.61% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +40.0% | $5.00 | $4.81 | -3.80% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +166.7% | $5.20 | $5.44 | +4.62% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -166.7% | $5.83 | $5.62 | -3.60% |
Q2 FY2026-0.40%
Report Date
May 7, 2026
EPS Beat/Miss
-50.0%
Price Before
$4.94
Price After
$4.92
Q1 FY2026+0.69%
Report Date
Feb 26, 2026
EPS Beat/Miss
+50.0%
Price Before
$4.37
Price After
$4.40
Q4 FY2025+2.56%
Report Date
Nov 5, 2025
EPS Beat/Miss
-200.0%
Price Before
$3.91
Price After
$4.01
Q3 FY2025+0.26%
Report Date
Aug 6, 2025
EPS Beat/Miss
+150.0%
Price Before
$3.88
Price After
$3.89
Q2 FY2025+1.61%
Report Date
May 8, 2025
EPS Beat/Miss
-125.0%
Price Before
$3.73
Price After
$3.79
Q1 FY2025-3.80%
Report Date
Feb 27, 2025
EPS Beat/Miss
+40.0%
Price Before
$5.00
Price After
$4.81
Q4 FY2024+4.62%
Report Date
Nov 5, 2024
EPS Beat/Miss
+166.7%
Price Before
$5.20
Price After
$5.44
Q3 FY2024-3.60%
Report Date
Aug 6, 2024
EPS Beat/Miss
-166.7%
Price Before
$5.83
Price After
$5.62
Avg Beat Reaction+0.44%
Avg Miss Reaction+0.04%
Beat Rate4 / 8 quarters
Largest Move+4.62% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTKB ends December
Cytek Biosciences, Inc. (CTKB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.12 — missing the analyst consensus of $-0.08 by -50.0%. The next CTKB earnings date is expected around September 1, 2026.
Each quarter, investors track CTKB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTKB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTKB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTKB earnings · 5 questionsCytek Biosciences, Inc.'s next earnings report is expected around September 1, 2026. CTKB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTKB historically reports after market close (AMC).
CTKB earnings datewhen is CTKB earningsCTKB next earnings datewhen does CTKB report earningsCTKB earnings calendar
▸ Source: FMP · Cytek Biosciences, Inc. SEC filings · US GAAP · Cytek Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026